25 February 2019
: Case report
Clindamycin: An Unusual Cause of Acute Kidney Injury
Mistake in diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy
Pratima Subedi12ABEF, Ayesha Chowdhury12ABEF, Kristina Tanovic12BE, Igor Dumic12AEFG*DOI: 10.12659/AJCR.913779
Am J Case Rep 2019; 20:248-251
Abstract
BACKGROUND: Medications are one of the most common causes of acute kidney injury (AKI). Elderly patients with diabetes mellitus and chronic kidney disease seem to be at particularly high risk for development of medication-induced AKI. Among antibiotics, the most commonly implicated agents are aminoglycosides, cephalosporins, trimethoprim-sulfamethoxazole, acyclovir, and amphotericin. Despite its widespread use, clindamycin has been rarely associated with AKI.
CASE REPORT: A 52-year-old male patient with type II insulin dependent diabetes mellitus without diabetic nephropathy was treated with clindamycin for chronic osteomyelitis. Five days following initiation of therapy, he developed nausea, poor appetite, decrease in urine output, and profound generalized weakness. His symptoms were initially attributed to gastrointestinal side effects of clindamycin and he was advised to take it with food and to hydrate himself vigorously. Despite this change, his symptoms progressed and he developed hematuria and AKI which prompted hospital admission. Extensive workup for AKI that included evaluation for pre-renal, intrinsic renal, and post-renal etiologies failed to point to other etiologies apart from clindamycin-induced AKI. Following cessation of medication and temporary renal replacement therapy (RRT), his renal function returned to baseline.
CONCLUSIONS: We present a case of clindamycin-induced AKI that was diagnosed after a delay due to uremia symptoms being mistakenly attributed to gastrointestinal side effects of clindamycin. Although rare, clindamycin can be a cause of AKI and clinician should be aware of this association in order to recognize and treat it in timely manner.
Keywords: Abnormalities, Drug-Induced, Acute Kidney Injury, clindamycin, Diabetes Mellitus, Type 2, Hematuria, Oliguria, Uremia, Anti-Bacterial Agents, Middle Aged, osteomyelitis
SARS-CoV-2/COVID-19
29 March 2023 : Editorial
Med Sci Monit In Press; DOI: 10.12659/MSM.940519
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
In Press
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939200
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939365
28 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939387
27 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939170
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347